Estimated GFR Decline and Tubular Injury Biomarkers With Intensive Blood Pressure Control

Current clinical practice guidelines recommend a blood pressure (BP) target of 130/80mm Hg in those with and without chronic kidney disease (CKD) to reduce morbidity and mortality.1 These guidelines are supported by recent evidence from clinical trials, including the Systolic Blood Pressure Intervention Trial (SPRINT), which showed reduced cardiovascular events and all-cause mortality with more intensive systolic BP (SBP) control in this high-risk population.2 Commendably, the investigators thoroughly investigated and reported adverse effects associated with intense BP control.

https://ift.tt/2yYf2i4